Burtscher, Johannes
Vanderriele, Paul-Emmanuel
Legrand, Matthieu
Predel, Hans-Georg
Niebauer, Josef
O’Keefe, James H.
Millet, Grégoire P.
Burtscher, Martin http://orcid.org/0000-0002-5232-3632
Funding for this research was provided by:
University of Innsbruck and Medical University of Innsbruck
Article History
Accepted: 2 July 2022
First Online: 18 July 2022
Declarations
:
: No sources of funding were used to assist in the preparation of this article. Open access funding was provided by University of Innsbruck and Medical University of Innsbruck.
: James Keefe is a participant in the Speaker Bureau for Amgen, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Janssen and Lilly. He is also Chief Medical Officer and Founder of CardioTabs, a nutraceutical company, and has a major ownership interest in that company. Hans-Georg Predel holds a leadership position in the German Hypertension Society. Johannes Burtscher, Paul-Emmanuel Vanderriele, Matthieu Legrand, Josef Niebauer, Grégoire Millet and Martin Burtscher declare that they have no potential conflicts of interest relevant to the content of this review.
: Conceptualization, JB, MB; literature review and discussion, JB, PEV, ML, HGP, JN, JHO, GPM, MB; illustration, JB; writing and proof reading, JB, PEV, ML, HGP, JN, JHO, GPM, MB. All authors read and approved the final manuscript.